8-K: Amwell Exceeds Q3 Guidance, Narrows 2025 EBITDA Loss

Amwell reported third-quarter 2025 financial results, surpassing revenue guidance and narrowing its full-year adjusted EBITDA loss outlook, driven by strategic execution and AI-powered platform adoption.

Summary

• Total Revenue for Q3 2025 was $56.3 million, exceeding previously provided financial guidance.
• Subscription revenue reached $30.9 million in Q3 2025.
• Amwell Medical Group (AMG) visit revenue was $21.2 million for Q3 2025.
• Gross margin for Q3 2025 stood at 52.4%.
• Net loss for Q3 2025 was ($31.9) million, compared to ($19.5) million in Q2 2025.
• Adjusted EBITDA for Q3 2025 was ($12.7) million, compared to ($4.7) million in Q2 2025.
• Total visits in Q3 2025 were 1.1 million.
• Revised 2025 full-year revenue guidance is now in the range of $245 million to $248 million, a slight adjustment from the previous $245 million to $250 million.
• 2025 full-year AMG visits guidance remains unchanged at 1.3 million to 1.35 million.
• The company narrowed its 2025 full-year Adjusted EBITDA guidance to a range of ($45) million to ($42) million, an improvement from the previous ($50) million to ($45) million.
• Q4 2025 revenue is projected to be in the range of $51 million to $54 million.
• Q4 2025 Adjusted EBITDA is projected to be in the range of ($15) million to ($12) million.
• The objective to achieve positive cash flow from operations by year-end 2026 was reiterated.

Sentiment

Score: 7

Explanation: Amwell's Q3 performance surpassed revenue guidance and improved its full-year Adjusted EBITDA outlook, indicating effective cost management and strategic execution. However, the company continues to report net losses and negative Adjusted EBITDA, alongside a slight reduction in the upper end of its full-year revenue guidance. The reiteration of positive cash flow by year-end 2026 is a key positive, but current cash burn remains a factor.

Positives

• Third-quarter 2025 total revenue of $56.3 million surpassed the previously provided financial guidance.
• The company achieved a strong gross margin of 52.4% in Q3 2025.
• Full-year 2025 Adjusted EBITDA guidance was narrowed to a better range of ($45) million to ($42) million, indicating improved cost management expectations.
• The company reiterated its strategic objective to achieve positive cash flow from operations by year-end 2026.
• Management highlighted leveraging an enterprise-grade platform increasingly powered by AI infrastructure and nearly two decades of telehealth expertise.

Negatives

• Net loss increased to ($31.9) million in Q3 2025 from ($19.5) million in Q2 2025.
• Adjusted EBITDA worsened to ($12.7) million in Q3 2025 from ($4.7) million in Q2 2025.
• Total revenue of $56.3 million in Q3 2025 is lower than $61.046 million reported in Q3 2024.
• The upper end of the revised 2025 full-year revenue guidance was slightly lowered from $250 million to $248 million.
• Cash and cash equivalents decreased from $228,316 thousand at December 31, 2024, to $200,888 thousand at September 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, was ($48,598) thousand.

Risks

• Ability to successfully transition clients to the Converge platform without significant attrition.
• Ability to renew and upsell the existing client base.
• Uncertainty regarding the continuation of the Defense Health Agency (DHA) relationship beyond July 2026 with comparable financial terms.
• Weak growth and increased volatility in the broader telehealth market.
• Ability to adapt to rapid technological changes and maintain competitive advantage.
• Increased competition from existing and potential new participants in the healthcare industry.
• Changes in healthcare laws, regulations, or trends and the ability to operate effectively in a heavily regulated healthcare industry.
• Ability to comply with federal and state privacy regulations, such as HIPAA.
• Significant liability that could result from a cybersecurity breach or data privacy incident.
• Ability to commence and complete strategic transformation initiatives and the potential impact of such initiatives on operations and financial performance.

Future Outlook

The company revised its full-year 2025 revenue guidance to a range of $245 million to $248 million and narrowed its Adjusted EBITDA guidance to between ($45) million and ($42) million. For Q4 2025, revenue is projected to be $51 million to $54 million, with Adjusted EBITDA between ($15) million and ($12) million. Amwell reiterated its objective to achieve positive cash flow from operations by year-end 2026.

Management Comments

• "Our third quarter performance surpassed guidance and reflects continued execution of our strategic plan to reach break-even cash flow from operations by year-end 2026." Dr. Ido Schoenberg, Chairman and CEO.
• "We are leveraging our enterprise-grade platform—increasingly powered by AI infrastructure and nearly two decades of telehealth expertise backed by millions of digital-first care encounters—to deliver substantial value for customers while maintaining exceptional operational efficiency." Dr. Ido Schoenberg, Chairman and CEO.
• "Healthcare organizations are increasingly challenged by fragmentation across multiple point solutions, and the market is moving in our direction." Dr. Ido Schoenberg, Chairman and CEO.
• "Amwell provides a scalable and reliable technology-enabled care backbone that delivers one platform, one user experience, and one data infrastructure." Dr. Ido Schoenberg, Chairman and CEO.
• "We give customers complete flexibility to select from the rapidly growing array of clinical programs that best serve their needs while safely realizing the promise of AI-driven automation coupled with the compliance and clinical integrity of certified care providers—an approach that drives meaningful improvements in both clinical and financial outcomes." Dr. Ido Schoenberg, Chairman and CEO.

Industry Context

Amwell positions itself as a key solution to the prevalent fragmentation in the healthcare industry, offering a unified, technology-enabled care platform. The company's emphasis on AI infrastructure and digital-first care aligns with broader industry trends towards integrated, efficient, and technologically advanced healthcare delivery models. Management believes the market is shifting towards comprehensive platforms over disparate point solutions, which favors Amwell's strategic approach.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or global benchmarks within the telehealth or SaaS healthcare industry. The analysis focuses on Amwell's internal performance and strategic positioning.

Related Party Transactions

• Accounts receivable included $1,184 thousand from related parties as of September 30, 2025.
• Deferred revenue included $45 thousand from related parties as of September 30, 2025.
• Revenue included $744 thousand from related parties for the three months ended September 30, 2025.
• Revenue included $2,009 thousand from related parties for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: The better-than-expected Q3 performance and improved EBITDA outlook could instill confidence, but continued net losses and cash burn remain areas of concern. The reiterated long-term goal of positive cash flow by 2026 is a key driver for future value.
• Customers (Payers and Health Systems): Benefit from Amwell's comprehensive, AI-powered, and integrated technology-enabled care platform, offering flexibility and potential for improved clinical and financial outcomes.
• Employees: The mention of severance and strategic transformation costs in the non-GAAP reconciliation suggests ongoing organizational adjustments, which could impact employees through restructuring or changes in roles.

Next Steps

• Host a conference call on November 4, 2025, at 5 p.m. ET to discuss the financial results.
• Continue execution of the strategic plan to reach break-even cash flow from operations by year-end 2026.
• Focus on successfully transitioning clients to the Converge platform.
• Work on renewing and upselling the client base.
• Adapt to rapid technological changes in the healthcare industry.
• Ensure compliance with evolving healthcare laws and regulations.
• Commence and complete strategic transformation initiatives to optimize the sales, growth organization, and overall cost structure.

Key Dates

Recommendation

While Amwell exceeded Q3 revenue guidance and narrowed its full-year Adjusted EBITDA loss outlook, demonstrating progress in operational efficiency and strategic execution, the company continues to operate at a net loss and negative Adjusted EBITDA. The cash burn, though improving, still exists. The reiteration of achieving positive cash flow from operations by year-end 2026 is a significant long-term positive, but the path to sustained profitability and positive cash flow needs further demonstration. The slight reduction in the upper end of the 2025 revenue guidance also warrants caution. Investors should hold to observe continued execution on strategic initiatives and progress towards the 2026 cash flow target before making further investment decisions.

Keywords

Telehealth, SaaS healthcare, Digital health, Amwell, AMWL, Q3 2025 earnings, Financial results, Healthcare technology, Adjusted EBITDA, Revenue guidance, AI healthcare